Leqembi autoinjector is now available for at-home use in early Alzheimer's disease, delivering the anti-amyloid monoclonal antibody lecanemab subcutaneously. This expands treatment access beyond infusion centers and may reduce healthcare utilization burden for patients with mild cognitive impairment or mild dementia.
Key Points
- At-home subcutaneous autoinjector reduces clinic visits and resource demand
- Initiation: 500 mg weekly; maintenance: 360 mg after 18 months of treatment
- MRI monitoring required to detect amyloid-related imaging abnormalities
Longevity Analysis
Leqembi targets amyloid-beta pathology in early-stage cognitive decline, addressing a root mechanism rather than symptom management alone. The shift to at-home delivery removes logistical barriers that previously prevented or delayed treatment initiation in patients who meet diagnostic criteria. For individuals with early cognitive impairment, consistent administration of an anti-amyloid agent before neurodegeneration accelerates may alter disease trajectory—though the long-term cognitive outcomes and durability of response remain under active observation. The need for regular MRI surveillance reflects the known risk of amyloid-related imaging abnormalities and underscores the importance of informed patient selection and monitoring protocols.
Original published by LT Wire.